AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection

Published: 29 October 2024

  • Views:

    Views Icon 1593

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.

  • To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
  • Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
  • Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
  • Don't miss the key take aways from our Highlights series.

More from this programme

Part 1

View From the Thoraxcenter

1 session
View from the Thoraxcenter: AHA 24 Late-breaking Preview Watch now

Part 2

Late-Breaker Discussions with Dr Harriette Van Spall

5 sessions
ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Watch now
NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Watch now
SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Watch now
FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Watch now
REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Watch now

Part 3

Expert Interviews

4 sessions
LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Watch now
LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Watch now
Mavacamten: Real-World Experience from 22 Months of the REMS Program Watch now
VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy Watch now

Part 4

Highlights

1 session
Coming Soon Watch now

About the episode

AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.

 

Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).

 

VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3 trial in the United States investigating the use of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy who are eligible and willing to undergo SRT procedures. 112 patients were enrolled in the trial and were followed-up at week 16 and from baseline to week 16. The primary outcome measures were a composite of the decision to proceed with SRT and to remain guideline eligible for SRT.

 

Interview Questions:
1.    What are the current unmet needs in hypertrophic cardiomyopathy management?
2.    Could you tell us about the mechanism of action behind mavacamten?
3.    What was the study design and patient population?
4.    What were the key findings?
5.    What are the take-home messages for practice?
6.    What further research is needed in this area?

 

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.

Faculty Biographies

Milind Y Desai

Milind Y Desai

Professor of Medicine

Dr Milind Desai works as the Director of the Hypertrophic Cardiomyopathy Center at the Heart, Vascular and Thoracic Institute at Cleveland Clinic. He also serves as a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. 

Alongside holding the Haslam Family Endowed Chair in Cardiovascular Medicine, Dr Desai has dual appointments in the Departments of Cardiovascular Medicine, within the Section of Cardiovascular Imaging, and Radiology. He is also a visiting professor at the University of Oxford, UK.

Dr Desai's clinical interests are heart valve disease, hypertrophic cardiomyopathy, aortic disorders, complex coronary artery disease, pericardial disease, and radiation heart disease. Dr Desai has a special interest in multimodality cardiovascular imaging, including echocardiogram, computed tomography (CT) scan and magnetic resonance imaging (MRI).

View full profile

Comments

You must be to comment. If you are not registered, you can register here.